Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in Alternative Bio, alongside an in-depth research partnership with the Wuxi-based biotech firm.
Alternative Bio’s Innovative Drug Development
Alternative Bio, founded by three serial entrepreneur scientists, focuses on developing small molecule targeted innovative drugs for major diseases such as tumors and inflammation. The company’s approach involves regulating cellular states by modulating ribosome and kinase methylation switches.
Collaboration on Pan-Cancer Inhibitor
The first collaboration program between Xtalpi and Alternative Bio is a pan-cancer small molecule inhibitor targeting the RAS-MAPK signaling pathway, particularly those associated with RAS mutations. This pathway is a key driver in various cancers, making it a promising target for new therapies.
Investigational Drug for Acute Pancreatitis
Alternative Bio’s other investigational drug is a small molecule inhibitor for the treatment of acute pancreatitis. Pre-clinical studies have shown good pharmacokinetics and efficacy, as well as a relatively ideal safety window, indicating potential for further development.-Fineline Info & Tech
